These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21288775)

  • 1. ART for children: what to start and when to switch.
    Sutcliffe CG; Moss WJ
    Lancet Infect Dis; 2011 Apr; 11(4):254-5. PubMed ID: 21288775
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 3. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 4. Switch study of nevirapine.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.
    Chiappini E; Galli L; Tovo PA; Gabiano C; de Martino M;
    Clin Exp Immunol; 2005 May; 140(2):320-4. PubMed ID: 15807857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Running with scissors: using antiretroviral therapy without monitoring viral load.
    Smith DM; Schooley RT
    Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496
    [No Abstract]   [Full Text] [Related]  

  • 7. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current world literature.
    Curr Opin HIV AIDS; 2012 Mar; 7(2):203-9. PubMed ID: 22314405
    [No Abstract]   [Full Text] [Related]  

  • 10. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 11. [HIV eradication--facts and fiction].
    Jaeger H; Wolf E
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
    [No Abstract]   [Full Text] [Related]  

  • 12. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.
    Asboe D; Aitken C; Boffito M; Booth C; Cane P; Fakoya A; Geretti AM; Kelleher P; Mackie N; Muir D; Murphy G; Orkin C; Post F; Rooney G; Sabin C; Sherr L; Smit E; Tong W; Ustianowski A; Valappil M; Walsh J; Williams M; Yirrell D;
    HIV Med; 2012 Jan; 13(1):1-44. PubMed ID: 22171742
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV meds: keeping trouble at bay.
    Daughtry LM; Bankston JB; Deshotels JM
    RN; 2002 Feb; 65(2):31-5; quiz 36. PubMed ID: 15328865
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring of antiretroviral therapy.
    Rakhmanina NY; van den Anker JN; Soldin SJ
    AIDS Patient Care STDS; 2004 Jan; 18(1):7-14. PubMed ID: 15006189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics and evolution of HIV-1 during structured treatment interruptions.
    Frost SD
    AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.